Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgical Conditions During Laparoscopic Bariatric Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02703909
Recruitment Status : Completed
First Posted : March 9, 2016
Results First Posted : June 21, 2018
Last Update Posted : June 21, 2018
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Terri Monk, University of Missouri-Columbia

Brief Summary:
Obesity affects more than 78 million adults in the United States and it is estimated that 35% of the US population is obese. Currently, more than 179,000 bariatric procedures are performed in the US each year with the majority of these surgeries using laparoscopic techniques. Surgeons often request deep neuromuscular blockade (NMB) during surgery, but there is no evidence that a deep NMB improves surgical conditions and that the surgeons can discriminate between a moderate and deep NMB. There is also evidence that maintaining low insufflation pressures during laparoscopic surgery may decrease postoperative pain. The goal of this prospective, randomized, assessor-blinded controlled trial is to test the hypothesis that deep NMB provides optimal surgical conditions during laparoscopic bariatric surgery in the morbidly obese patient. It will also determine if deep NMB allows the surgeon to utilize lower insufflation pressure and decreases postoperative pain requirements after laparoscopic bariatric surgery.

Condition or disease Intervention/treatment Phase
Morbid Obesity Drug: Rocuronium Device: Insufflation pressure Phase 4

Detailed Description:

Subjects will be randomized to one of four groups:

  1. moderate neuromuscular block (NMB) + 10 mm insufflation pressure (IP);
  2. moderate NMB + 15 mm IP;
  3. deep NMB + 10 mm IP; or
  4. deep NMB + 15 mm IP.

A moderate NMB block will be defined as 2-3 twitches in the train of four (TOF) and a deep NMB will be defined as 0-1 posttetanic count. The surgeons will be asked to rate their satisfaction with the surgical conditions using a five-point ordinal scale ranging from 1 (extremely poor) to 5 (optimal conditions). The first rating will occur at the beginning of the procedure when the NMB level is stable at either a deep or moderate block and the intra-abdominal pressure is either 10 or 15 mm Hg (per randomization). The surgeon will be blinded to the insufflation pressure at this point. If the surgical conditions are rated as extremely poor or poor, the level of the neuromuscular block can be increased and/or the insufflation pressure can be increased to 15 mm Hg.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: A Prospective Randomized Clinical Trial Evaluating Surgical Conditions During Laparoscopic Bariatric Surgery With Deep Versus Moderate Neuromuscular Blockade
Actual Study Start Date : May 2016
Actual Primary Completion Date : May 30, 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: moderate NMB + 10 mm IP
participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
Drug: Rocuronium
Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Other Name: Zemuron

Device: Insufflation pressure
The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Other Name: intra-abdominal pressure

Active Comparator: moderate NMB + 15 mm IP
participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
Drug: Rocuronium
Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Other Name: Zemuron

Device: Insufflation pressure
The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Other Name: intra-abdominal pressure

Experimental: deep NMB + 10 mm IP
participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
Drug: Rocuronium
Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Other Name: Zemuron

Device: Insufflation pressure
The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Other Name: intra-abdominal pressure

Experimental: deep NMB + 15 mm IP
participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
Drug: Rocuronium
Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Other Name: Zemuron

Device: Insufflation pressure
The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Other Name: intra-abdominal pressure




Primary Outcome Measures :
  1. Surgeon Satisfaction Scale [ Time Frame: day of surgery ]
    The surgeon will grade his satisfaction with the surgical conditions using a 5 point scale with 1 - extremely poor; 2 - poor; 3 - acceptable; 4. good; 5 - optimal surgical conditions


Secondary Outcome Measures :
  1. Number and Percentage of Subjects With Success at Low (10 mm) Insufflation Pressure [ Time Frame: day of surgery ]
    The patients will be randomized to an initial insufflation pressure of 10 or 15 mm hg. If the surgeons are not satisfied with the initial operating conditions, the insufflating pressure will be increase to 15 mm Hg (if not already at that level). This will be reported as the percentage of patients who were able to have their entire surgery performed at an insufflation pressure of 10 mm Hg.

  2. Postoperative Opioid Requirement [ Time Frame: day of surgery until hospital discharge (approximately 2-3 days) ]
    The participants will be given iv fentanyl or hydromorphone after surgery. They will also be given po oxycodone. The investigators will collect data on the amount of opioid that is required after surgery. This will be reported as morphine equivalents using the morphine equivalent calculator at:



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • ASA I-III
  • BMI ≥ 35

Exclusion Criteria:

  • Inability to obtain written informed consent
  • Pregnancy or breastfeeding
  • Allergy to rocuronium, sugammadex, or any anesthetic agents used in the protocol
  • Known or suspected neuromuscular disorders
  • Significant renal disease with a serum creatinine ≥ 2 mg/dl f. Significant liver disease g. A family history of malignant hyperthermia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02703909


Locations
Layout table for location information
United States, Missouri
University Hospital
Columbia, Missouri, United States, 65212
Sponsors and Collaborators
University of Missouri-Columbia
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Terri G Monk, MD University of Missouri-Columbia
  Study Documents (Full-Text)

Documents provided by Terri Monk, University of Missouri-Columbia:

Layout table for additonal information
Responsible Party: Terri Monk, Professor, Anesthesiology, University of Missouri-Columbia
ClinicalTrials.gov Identifier: NCT02703909     History of Changes
Other Study ID Numbers: 2004620
First Posted: March 9, 2016    Key Record Dates
Results First Posted: June 21, 2018
Last Update Posted: June 21, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Terri Monk, University of Missouri-Columbia:
morbid obesity
laparoscopic surgery
neuromuscular blockade
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity, Morbid
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Rocuronium
Neuromuscular Nondepolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs